GSK-Backed DB-1324 Trial Marks Early Progress in Advanced Gastrointestinal Cancer

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

The study, titled “A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors,” aims to test a new cancer drug in people with hard-to-treat gut tumors. It focuses on basic safety, how the drug moves in the body, and early signs that it may slow or shrink tumors.

The treatment being tested is DB-1324, an intravenous cancer drug from DualityBio with GSK as a collaborator. It is designed for advanced gastrointestinal cancers where current options are limited and aims to offer another line of therapy if results are positive.

The trial is an interventional study in two parts, Phase 1 and Phase 2, and is not randomized, meaning patients are assigned to dose groups in sequence rather than by chance. It is open-label, so both doctors and patients know what dose is given, and the main goal is treatment, not prevention or diagnosis.

Phase 1 includes dose escalation, backfill, and dose expansion groups to find the right range and schedule for DB-1324 while tracking safety. Phase 2 will then test one or more of these dose plans in larger groups to confirm early signs of benefit seen in the first phase.

The study is currently listed as recruiting, indicating active site set-up and patient enrollment, which is an early but important milestone for a first-in-human cancer drug. The most recent update was submitted on 2026-05-19, signaling that the protocol or status has been refreshed and that operational progress is ongoing.

Early-stage oncology trials rarely move stocks on their own, but this update matters because it shows GSK and DualityBio are executing on a pipeline aimed at high-need gastrointestinal cancers. For GSK investors, steady progress in novel cancer assets can support the long-term growth story and help offset patent risk in mature products.

For DualityBio, successful advancement of DB-1324 could lift its profile as a partner of choice in next-generation oncology drugs and enhance its bargaining power in future licensing deals. In a crowded cancer field with players like Roche, BMS, and Merck, any unique data signal in gastrointestinal tumors could offer a niche edge, even if full commercial impact is years away.

Given the study is still in Phase 1/2, investors should view this as a long-duration catalyst with binary risk tied to future safety and tumor response readouts rather than near-term revenue. The trial remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.